New medication, marketed by
Servier Laboratories in Australia,
to treat atypical schizophrenia has
been PBS listed effect as of 01 Nov.
Professor David Castle from
Melbourne said the availability
of Latuda (lurasidone HCl) had
been “eagerly anticipated by the
psychiatric community”.
The treatment has been available
in the United States since 2011,
Canada since 2012 and Europe
since 2013.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Nov 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.